| Objective:To observe the change of the level of serum advanced glycation end-products(AGEs), blood glucose and blood lipid before and after Using alpha lipoic acid in DPN patients, and to explore its possible mechanisms. Methods: On the order of selected 130 hospitalized patients witch meets the criteria in The secod Cadres health care department and The endocrine department of xinjiang uygur muncipal people’s hospital from December 2014 to October 2015.According to random number table method, divided the selected object into control group and treatment group, 65 cases each, both group given mecobalamine injection 1000 ug with physiological saline injection 100 ml, once-daily Intravenous drip, only the treatment group given alpha lipoic acid injection 600 mg and physiological saline 250 ml, Intravenous drip once a day. Continue treatment for 2 weeks,then observed the difference of Nerve conduction velocity, TSS score and the level of serum AGEs, blood glucose and blood lipid between before and after treatment of 2 groups.To analyze the data with statistical package for social science(SPSS) 17.0 software. Results:1. After treatment: The TSS score decreased in both groups(P < 0.01),the difference was statistically significant; The median nerve motor Nerve conduction velocity,sensory nerve conduction velocity and common peroneal nerve motor nerve conduction velocity,sensory nerve conduction velocity were increased before treatment(P < 0.01),the difference was statistically significant. The TSS score in Treatment group was lower than those in control group(P < 0.01) the difference was statistically significant; Nerve conduction velocity were higher than those in control group(P < 0.05) the difference was statistically significant.2. After treament : There is no significant changes in the serum AGEs compared with before treatment in Control group:(P>0.05), the serum AGEs decrease compared with before treatment in treatment group:(P<0.01), the difference was statistically significant. After treatment: the serum levels of AGEs in the treatment group is loewr than in the control group(P<0.01), a statistically significant difference.3. After treatment: The blood glucose lower than before treatment In two sets(P<0.01), the difference was statistically significant.there is no significant difference between the treatment group and the control group(P>0.05). No differences in lipid levels between the two groups after treatment.4. Serum levels of AGEs have positive correlation with age, course, TSS score, glycated hemoglobin levels, systolic blood pressure(r=0.787 r=0.748 r=0.766 r=0.196 r=0.483 P<0.05) and negative correlation with median nerve motor nerve conduction velocity and median nerve sensory nerve conduction velocity, common peroneal nerve motor nerve conduction velocity and common Peroneal nerve and Sensory nerve conduction velocity(r=-0.696 r=-0.507 r=-0.594 r=-0.556 P<0.01). Have no related to Fasting plasma glucose(FPG), Body mass index(BMI) and triglyceride(TG), cholesterol(CHDL), high-density lipoprotein(HDL-C), low-density lipoprotein(LDL-C)(both P>0. 05).5.With serum AGEs as the dependent variable, To age,duration, HbAlc, systolic blood pressure as the independent variable. multiple linear regression analysis showed: age, duration of diabetes mellitus, systolic blood pressure levels, scores of HbAlc and are independently associated with serum AGEs. Conclusion:ALA in combination with Mecobalamine can obviously improve the symptoms and signs of diabetic peripheral neuropathy in the short term,It’s Curative effect is better than using Mecobalamine alone. But it is not obvious to improve the level of blood sugar, blood fat in the short term, witch it’s Serum AGEs concentration associated with diabetic peripheral neuropathy severity; ALA may through the role of decrease the Serum concentration of AGEs to improve the clinical symptoms of patients with DPN. |
PDF Full Text Request